Madhukar H. Trivedi, M.D., is Professor, Chief of the Division of Mood Disorders, and Director of the Comprehensive Center for Depression in the Department of Psychiatry at UT Southwestern Medical Center. Dr. Trivedi, holder of the Betty Jo Hay Distinguished Chair in Mental Health, is an established efficacy and effectiveness researcher in the treatment of depression. His research focuses on pharmacological, psychosocial, and nonpharmacological treatments for depression.
Dr. Trivedi has been a Principal Investigator in multiple clinical trials funded through the National Institute of Mental Health (NIMH) and the Texas Department of Mental Health. He currently serves as Principal Investigator of the National Institute of Drug Abuse (NIDA)-funded “Stimulant Reduction Intervention using Dosed Exercise (STRIDE)” study, which tests the effectiveness of adding exercise to treatment as usual to improve drug treatment outcomes. Dr. Trivedi also serves as Principal Investigator of the Texas Node of the NIDA-funded Clinical Trials Network.
He previously served as Principal Investigator for three NIMH grants – “CBASP Augmentation for Treatment of Chronic Depression (REVAMP),” “Treatment with Exercise Augmentation for Depression (TREAD),” and “Computerized Decision Support System for Depression (CDSS-D).” He was also the Principal Investigator of the Depression Trials Network “Combining Medications to Enhance Depression Outcomes (CO-MED)” trial, which focused on using specific antidepressant combinations to increase remission rates by treating a broader spectrum of depressed patients and by capitalizing on additive pharmacological effects. In addition, Dr. Trivedi served as the Co-Principal Investigator of the NIMH-funded project entitled “Sequenced Treatment Alternatives to Relieve Depression (STAR*D).”
Most recently, Dr. Trivedi was selected to be the Lead PI for the team conducting the “Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC)” project. The project, which is at the core of the NIMH’s initiative to identify a biosignature for depression, uses neuroimaging, EEG, clinical and behavioral phenotypes, and other blood-based biological markers to begin the development of a biosignature for depression.
Dr. Trivedi has been involved with the National Network of Depression Centers (NNDC) since its inception and led a successful effort through the Research Domain Committee to formulate the Comprehensive Assessment Package being used in the NNDC. Dr. Trivedi serves as the Co-Chair of the NNDC’s newly formed Biomarker Task Group.
Dr. Trivedi has received numerous awards including the Gerald L. Klerman Award from the National Depressive and Manic-Depressive Association’s Scientific Advisory Board and the Psychiatric Excellence Award from the Texas Society of Psychiatric Physicians. Dr. Trivedi has mentored multiple psychopharmacology postdoctoral fellows and research-track residents in Mood and Anxiety Disorders and is the Principal Investigator of an NIMH-funded postdoctoral T32 training program. He is or has been a member of several institutional review groups of the NIMH. Dr. Trivedi has published more than 420 articles and chapters related to the diagnosis and treatment of mood disorders.